PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-104.03%
Negative net income growth while VET stands at 114.44%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
2.94%
Some D&A expansion while VET is negative at -19.61%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
-204.55%
Negative yoy deferred tax while VET stands at 512.75%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
800.00%
SBC growth while VET is negative at -27.83%. John Neff would see competitor possibly controlling share issuance more tightly.
-34.38%
Both reduce yoy usage, with VET at -23.25%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-213.11%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.38%
Both reduce yoy usage, with VET at -23.25%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-58.82%
Both negative yoy, with VET at -10.62%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-3.44%
Both yoy CFO lines are negative, with VET at -3.52%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-1.41%
Negative yoy CapEx while VET is 46.19%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-85.62%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
100.00%
Purchases growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
No Data
No Data available this quarter, please select a different quarter.
73.24%
We have some outflow growth while VET is negative at -45.18%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-5.16%
We reduce yoy invests while VET stands at 28.65%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
51.16%
Debt repayment 1.25-1.5x VET's 37.57%. Bruce Berkowitz would see an edge in lowering interest burdens unless competitor invests in profitable expansions.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Buyback growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.